[go: up one dir, main page]

GB201806490D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number
GB201806490D0
GB201806490D0 GBGB1806490.7A GB201806490A GB201806490D0 GB 201806490 D0 GB201806490 D0 GB 201806490D0 GB 201806490 A GB201806490 A GB 201806490A GB 201806490 D0 GB201806490 D0 GB 201806490D0
Authority
GB
United Kingdom
Prior art keywords
novel formulation
formulation
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1806490.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Priority to GBGB1806490.7A priority Critical patent/GB201806490D0/en
Publication of GB201806490D0 publication Critical patent/GB201806490D0/en
Priority to PCT/IB2018/054769 priority patent/WO2019003150A2/en
Priority to KR1020207002640A priority patent/KR102722927B1/en
Priority to CN201880044074.1A priority patent/CN110958883A/en
Priority to CA3067147A priority patent/CA3067147A1/en
Priority to US16/621,309 priority patent/US12011506B2/en
Priority to IL271555A priority patent/IL271555B2/en
Priority to BR112019027915-6A priority patent/BR112019027915A2/en
Priority to JP2019572713A priority patent/JP7287906B2/en
Priority to MX2019015515A priority patent/MX392599B/en
Priority to RU2019140298A priority patent/RU2755710C2/en
Priority to AU2018291076A priority patent/AU2018291076B2/en
Priority to EP18823998.2A priority patent/EP3645003A4/en
Priority to TW107122227A priority patent/TWI830703B/en
Priority to CL2019003889A priority patent/CL2019003889A1/en
Priority to US18/503,232 priority patent/US20240091159A1/en
Priority to US19/186,796 priority patent/US20250262163A1/en
Ceased legal-status Critical Current

Links

GBGB1806490.7A 2017-06-30 2018-04-20 Novel formulation Ceased GB201806490D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB1806490.7A GB201806490D0 (en) 2018-04-20 2018-04-20 Novel formulation
EP18823998.2A EP3645003A4 (en) 2017-06-30 2018-06-27 ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS
JP2019572713A JP7287906B2 (en) 2017-06-30 2018-06-27 Combinations and their uses and treatments
RU2019140298A RU2755710C2 (en) 2017-06-30 2018-06-27 Combination, its application and methods for treatment using specified combination
CN201880044074.1A CN110958883A (en) 2017-06-30 2018-06-27 Combinations and uses and therapies thereof
CA3067147A CA3067147A1 (en) 2017-06-30 2018-06-27 Combination and uses and treatments thereof
US16/621,309 US12011506B2 (en) 2017-06-30 2018-06-27 Combination and uses and treatments thereof
IL271555A IL271555B2 (en) 2017-06-30 2018-06-27 Combination and uses and treatments thereof
BR112019027915-6A BR112019027915A2 (en) 2017-06-30 2018-06-27 low glycemic carbohydrate composition available, liquid nutritional composition, and, use of a carbohydrate composition
PCT/IB2018/054769 WO2019003150A2 (en) 2017-06-30 2018-06-27 Combination and uses and treatments thereof
MX2019015515A MX392599B (en) 2017-06-30 2018-06-27 Bilayer tablets containing dolutegravir sodium and rilpivirine hydrochloride
KR1020207002640A KR102722927B1 (en) 2017-06-30 2018-06-27 Combinations and their uses and treatments
AU2018291076A AU2018291076B2 (en) 2017-06-30 2018-06-27 Combination and uses and treatments thereof
TW107122227A TWI830703B (en) 2017-06-30 2018-06-28 Combination and uses and treatments thereof
CL2019003889A CL2019003889A1 (en) 2017-06-30 2019-12-27 Combination and uses and treatments thereof.
US18/503,232 US20240091159A1 (en) 2017-06-30 2023-11-07 Combination and Uses and Treatments Thereof
US19/186,796 US20250262163A1 (en) 2017-06-30 2025-04-23 Combination and Uses and Treatments Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1806490.7A GB201806490D0 (en) 2018-04-20 2018-04-20 Novel formulation

Publications (1)

Publication Number Publication Date
GB201806490D0 true GB201806490D0 (en) 2018-06-06

Family

ID=62236217

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1806490.7A Ceased GB201806490D0 (en) 2017-06-30 2018-04-20 Novel formulation

Country Status (1)

Country Link
GB (1) GB201806490D0 (en)

Similar Documents

Publication Publication Date Title
IL282617A (en) Aerosolisable formulation
IL282567A (en) Aerosolisable formulation
IL282523A (en) Aerosolisable formulation
IL276011A (en) Group b adenovirus-containing formulation
IL282589A (en) Aerosolisable formulation
GB201718035D0 (en) Aerosolisable formulation
GB201816447D0 (en) Formulation
IL282461A (en) Aerosolisable formulation
GB201809976D0 (en) Novel formulations
GB201701239D0 (en) Novel formulation
IL282697A (en) Aerosolisable formulation
GB201817863D0 (en) Aerosolisable formulation
GB201713724D0 (en) Formulation
IL284688A (en) Formulation
GB201706969D0 (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
GB201719464D0 (en) Formulation
GB2587402B (en) Formulation
GB201806498D0 (en) Novel formulation
GB201806490D0 (en) Novel formulation
GB201817866D0 (en) Aerosolisable formulation
GB201809575D0 (en) Formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)